logo-loader
viewFSD Pharma

Full interview: FSD Pharma 'hunkering down' on grow facility and 'doubling down' on biosciences effort

FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) CEO Raza Bokhari reveals 3Q highlights for the medically-focused cannabis company.

Bokhari says the Canadian company is 'hunkering down' on its cannabis grow facility and 'doubling down' on its biosciences effort, advancing its Phase 1 safety trials for its lead drug candidate PP 101 micro-PEA.

Quick facts: FSD Pharma

Price: 4.78 CAD

CSE:HUGE
Market: CSE
Market Cap: $38.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: FSD Pharma 'thrilled' to begin Phase 1 studies of its...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) BioSciences Division President Dr Ed Brennan tells Proactive the company has begun a Phase 1 human study of its anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA) after winning approval from the Ethics Committee of the Alfred Hospital in...

4 weeks, 1 day ago

2 min read